NCT00308100View on ClinicalTrials.gov

Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver Transplantation

PHASE4TerminatedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Intraoperative Complications
Interventions
DRUG

Hydroxyethylstarch 130/0.4

HES 130/0.4, administered intra- and perioperatively, max. daily dose: 33ml/kg BW; if needed, additionally albumin is administered (ratio crystalloid to colloid= 1:1)

DRUG

5% Albumin

5% albumin, administered intra- and perioperatively

Trial Locations (1)

100044

People's Hospital of Peking University, Beijing

Sponsors

Lead Sponsor

Fresenius Kabi
All Listed Sponsors
lead

Fresenius Kabi

INDUSTRY